Denali therapeutics announces significant program progress and expected key milestones in 2021 for its broad therapeutic portfolio in neurodegeneration

South san francisco, calif., jan. 08, 2021 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (bbb) for neurodegenerative diseases, today announced program progress and expected milestones for 2021, which chief executive officer, ryan watts, ph.d., will highlight during a corporate presentation at the 39th annual j.p. morgan healthcare conference on tuesday, january 12, at 10 a.m. eastern time.
DNLI Ratings Summary
DNLI Quant Ranking